Businesswire·2026-02-24 11:00Core Insights - Organigram Global Inc. is expanding its international product portfolio by launching Edison and BOXHOT medical cannabis vape and pastille products in Australia, aligning with the rising demand for alternatives to flower products in the Australian medical cannabis market [1] Product Launch and Market Strategy - The launch includes 10 product SKUs across Edison and BOXHOT brands, with Edison vapes featuring single-strain live terpenes from Canada's top-selling cultivars and pastilles designed for specific patient experiences [1] - BOXHOT will offer three top-selling botanical blends in proprietary 1.2g cartridges, emphasizing the trend towards ready-to-consume formats in the medical cannabis sector [1] Market Dynamics - Australia is recognized as a rapidly evolving medical cannabis market, with increasing approvals for access and a shift in clinician preferences towards non-flower options that provide consistent dosing and ease of use [1] - The company aims to leverage its expertise in high-quality, non-flower cannabis product formats to meet the growing demand in Australia and other regulated markets globally [1] Distribution and Partnerships - Organigram's products will be distributed through a partnership with Leafio, which will facilitate access to over 4,000 pharmacies across Australia [1] - The company will showcase its new product lineup at the United in Compassion Medical Cannabis Symposium in Brisbane, enhancing visibility among clinicians and industry participants [1] Corporate Growth and Acquisitions - The launch in Australia coincides with Organigram's proposed acquisition of Sanity Group, a leading German cannabis company, marking a significant step in its international expansion strategy [1]